Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2017 2
2018 1
2019 1
2020 4
2021 11
2022 8
2023 9
2024 14
2025 12
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O'Connor CM; VICTORIA Study Group. Armstrong PW, et al. N Engl J Med. 2020 May 14;382(20):1883-1893. doi: 10.1056/NEJMoa1915928. Epub 2020 Mar 28. N Engl J Med. 2020. PMID: 32222134 Free article. Clinical Trial.
A total of 691 patients (27.4%) in the vericiguat group and 747 patients (29.6%) in the placebo group were hospitalized for heart failure (hazard ratio, 0.90; 95% CI, 0.81 to 1.00). ...Symptomatic hypotension occurred in 9.1% of the patients in the vericiguat group …
A total of 691 patients (27.4%) in the vericiguat group and 747 patients (29.6%) in the placebo group were hospitalized for heart fai …
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial.
Reddy YNV, Butler J, Anstrom KJ, Blaustein RO, Bonaca MP, Corda S, Ezekowitz JA, Lam CSP, Lewis EF, Lindenfeld J, McMullan CJ, Mentz RJ, O'Connor C, Patel M, Ponikowski P, Rosano GMC, Saldarriaga CI, Senni M, Udelson J, Voors AA, Zannad F. Reddy YNV, et al. Eur J Heart Fail. 2025 Feb;27(2):209-218. doi: 10.1002/ejhf.3501. Epub 2024 Oct 30. Eur J Heart Fail. 2025. PMID: 39473305 Free PMC article. Clinical Trial.
The effect of vericiguat in patients with HFrEF without recent worsening HF remains unknown. The VICTOR (Vericiguat Global Study in Participants with Chronic Heart Failure) trial was designed to assess the efficacy and safety of vericiguat in patients with ej …
The effect of vericiguat in patients with HFrEF without recent worsening HF remains unknown. The VICTOR (Vericiguat Global Stu …
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.
Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Ezekowitz JA, Felker GM, Gates D, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, She L, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Zannad F; VICTOR Study Group. Butler J, et al. Lancet. 2025 Sep 27;406(10510):1341-1350. doi: 10.1016/S0140-6736(25)01665-4. Epub 2025 Aug 30. Lancet. 2025. PMID: 40897189 Clinical Trial.
Serious adverse events occurred in 717 (23.5%) of 3049 patients in the vericiguat group and 751 (24.6%) of 3049 patients in the placebo group. The most common adverse event was symptomatic hypotension (345 [11.3%] patients in the vericiguat group and 281 [9.2%] in t …
Serious adverse events occurred in 717 (23.5%) of 3049 patients in the vericiguat group and 751 (24.6%) of 3049 patients in the place …
Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA.
Chen C, Lv J, Liu C. Chen C, et al. Front Endocrinol (Lausanne). 2024 Mar 8;15:1335531. doi: 10.3389/fendo.2024.1335531. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38524633 Free PMC article. Review.
Vericiguat, the newest soluble guanylate cyclase (sGC) drug, is potentially beneficial in treating heart failure (HF). ...Therefore, the main objective of this meta-analysis was to comparatively analyze the effects of Vericiguat in the entire LVEF range based on pre …
Vericiguat, the newest soluble guanylate cyclase (sGC) drug, is potentially beneficial in treating heart failure (HF). ...Therefore, …
Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
Armstrong PW, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O'Connor CM, Pieske B, Ponikowski P, Shah SJ, Solomon SD, Voors AA, She L, Vlajnic V, Carvalho F, Bamber L, Blaustein RO, Roessig L, Butler J; VITALITY-HFpEF Study Group. Armstrong PW, et al. JAMA. 2020 Oct 20;324(15):1512-1521. doi: 10.1001/jama.2020.15922. JAMA. 2020. PMID: 33079152 Free PMC article. Clinical Trial.
The least-squares mean difference in scores between the 15-mg/d vericiguat and placebo groups was -1.5 (95% CI, -5.5 to 2.5; P = .47) and between the 10-mg/d vericiguat and placebo groups was -0.5 (95% CI, -4.6 to 3.5; P = .80). ...The proportions of patients who ex …
The least-squares mean difference in scores between the 15-mg/d vericiguat and placebo groups was -1.5 (95% CI, -5.5 to 2.5; P = .47) …
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, Butler J, Ponikowski P, Shah SJ, Solomon SD, Scalise AV, Mueller K, Roessig L, Gheorghiade M. Pieske B, et al. Eur Heart J. 2017 Apr 14;38(15):1119-1127. doi: 10.1093/eurheartj/ehw593. Eur Heart J. 2017. PMID: 28369340 Free PMC article. Clinical Trial.
AIMS: To determine tolerability and the optimal dose regimen of the soluble guanylate cyclase stimulator vericiguat in patients with chronic heart failure and preserved ejection fraction (HFpEF). ...Vericiguat was well tolerated (adverse events: vericiguat 10 …
AIMS: To determine tolerability and the optimal dose regimen of the soluble guanylate cyclase stimulator vericiguat in patients with …
Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Müller K, Roessig L, Pieske B; SOCRATES-REDUCED Investigators and Coordinators. Gheorghiade M, et al. JAMA. 2015 Dec 1;314(21):2251-62. doi: 10.1001/jama.2015.15734. JAMA. 2015. PMID: 26547357 Clinical Trial.
The primary analysis specified pooled comparison of the 3 highest-dose vericiguat groups with placebo, and secondary analysis evaluated a dose-response relationship with vericiguat and the primary end point. ...The exploratory secondary analysis suggested a dose-res …
The primary analysis specified pooled comparison of the 3 highest-dose vericiguat groups with placebo, and secondary analysis evaluat …
Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.
Lam CSP, Giczewska A, Sliwa K, Edelmann F, Refsgaard J, Bocchi E, Ezekowitz JA, Hernandez AF, O'Connor CM, Roessig L, Patel MJ, Pieske B, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Lam CSP, et al. JAMA Cardiol. 2021 Jun 1;6(6):706-712. doi: 10.1001/jamacardio.2020.6455. JAMA Cardiol. 2021. PMID: 33185650 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate clinical characteristics, outcomes, and treatment response to vericiguat according to prespecified index event subgroups and time from index HFH in the Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICT …
OBJECTIVE: To evaluate clinical characteristics, outcomes, and treatment response to vericiguat according to prespecified index event …
Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR.
Zannad F, Reddy YNV, Barash I, Anstrom KJ, Bonaca MP, Borentain M, Corda S, Teixeira PP, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, McMullan CJ, Mentz RJ, O'Connor CM, Ponikowski P, Rosano GMC, Saldarriaga C, Senni M, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Butler J; VICTOR Study Group. Zannad F, et al. J Am Coll Cardiol. 2025 Dec 16;86(24):2471-2491. doi: 10.1016/j.jacc.2025.08.051. Epub 2025 Aug 27. J Am Coll Cardiol. 2025. PMID: 40892609 Free article. Clinical Trial.
BACKGROUND: In the VICTOR (Vericiguat Global Study in Participants With Chronic Heart Failure) trial, in a contemporary ambulatory cohort with heart failure and reduced ejection fraction (HFrEF) and no recent hospitalization, the primary outcome of hospitalization for hear …
BACKGROUND: In the VICTOR (Vericiguat Global Study in Participants With Chronic Heart Failure) trial, in a contemporary ambulatory co …
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.
Butler J, Fioretti F, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Teixeira PP, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Zannad F. Butler J, et al. Eur Heart J. 2026 Feb 11;47(6):683-697. doi: 10.1093/eurheartj/ehaf655. Eur Heart J. 2026. PMID: 40884032 Free PMC article. Clinical Trial.
BACKGROUND AND AIMS: In the VICTOR trial (NCT05093933), vericiguat was neutral for the primary composite endpoint of cardiovascular death or hospitalization for heart failure (HF). ...This study reports detailed analysis on the effects of vericiguat on mortality. ME …
BACKGROUND AND AIMS: In the VICTOR trial (NCT05093933), vericiguat was neutral for the primary composite endpoint of cardiovascular d …
59 results